<DOC>
	<DOCNO>NCT00934258</DOCNO>
	<brief_summary>Previous study indicate variant status detoxification proteins different among Taiwanese ethnic group . For example , Taiwanese , major SNPs CYP2C9 CYP2C9*2 ( 430C &gt; T ) CYP2C9*3 ( 1075A &gt; C ) frequencies different Caucasians [ 11 ] . The second example frequency A ( TA ) 7TAA allele promoter area UGT1A1 gene substantially low , rate variation within cod region much high Taiwanese Caucasians ( 14.3 % vs. 35.7- 41.5 % 29.3 % vs. 0.1 % , respectively ) [ 12 ] . The third example frequency 388A &gt; G OATP2 gene Taiwanese ( 0.68 ) [ 13 ] European Americans ( 0.30 ) African Americans ( 0.74 ) [ 14 ] . Therefore , investigator hypothesize , Taiwanese SNPs detoxification protein modulate lipid-lowing effect RVA fenofibrate may different Caucasians .</brief_summary>
	<brief_title>Effect Genes Rosuvastatin Therapy Hyperlipidemia</brief_title>
	<detailed_description>Since April 2008 , start run multicenter , prospective , randomize , open-label , blind end-point classification trial test hypothesis Taiwan addition fibrate statin would provide reduction major coronary event patient diabetes atherosclerotic vascular disease metabolic syndrome . With advantage large-scaled prospective trial , also good opportunity identify simultaneously genetic determinant wide range interindividual variability phenotypic clinical response two major lipid-lowering drug class , rosuvastatin fenofibrate . The aim proposal find SNPs influence therapeutic effectiveness lipid lower therapy Taiwanese hyperlipidemic patient . A key feature use multiple drug-treated population sample get finding derive candidate gene genome-wide search SNP association marker drug efficacy well side effect . Thus promise pharmacogenomics metabolomics -- `` individualized medicine '' come true treat hyperlipidemia Taiwanese .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Men woman age 2079 year definite DM atherosclerotic vascular disease metabolic syndrome , define presence three follow risk factor : abdominal obesity ( waist circumference &gt; 90 cm men &gt; 80 cm woman ) , triglycerides &gt; 150 mg/dL , HDLcholesterol &lt; 40 mg/dL men &lt; 50 mg/dL woman , blood pressure &gt; 130/85 mm Hg , fast glucose &gt; 100 mg/dL ) . Those qualified lipid lower therapy accord Taiwanese national guideline ( LDLC 130190 mg/dL TG 200500 mg/dL HDLC &lt; 40 mg/dL TC/HDLC &gt; 5 ) . Any known contraindication statin fibrate therapy , Previous intolerance statin fibrate low high dos , Liver enzyme level 3 time upper limit normal , Pregnancy breastfeeding , Nephrotic syndrome , Uncontrolled diabetes mellitus ( HbA1c &gt; 9 ) , Uncontrolled hypothyroidism , Plasma LDLC level high 190 mg/dL triglyceride level high 500 mg/dL , Coronary heart disease event revascularisation within month , Congestive heart failure ( New York Heart Association classification IIIb IV ) , Hemodynamically important valvular heart disease , Gastrointestinal condition affect absorption drug , Treatment drug seriously affect pharmacokinetics statin fibrate , Unexplained creatine phosphokinase concentration six time upper limit normal , Lifethreatening malignancy , Treatment immuno suppressive lipid lower drug . Patients previously treat monotherapy statins fibrates qualify already titration dose high equivalent 5 mg/d rosuvastatin 160 mg/d SFC fenofibrate .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>gene</keyword>
	<keyword>rosuvastatin</keyword>
	<keyword>fenofibrate</keyword>
	<keyword>Cardiovascular ( CV ) disease</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>metabolic syndrome</keyword>
	<keyword>identify genetic determinant wide range interindividual variability phenotypic clinical response lipid-lowering drug class</keyword>
	<keyword>identify genetic susceptibility drug-related side effect .</keyword>
</DOC>